Endometriosis from initiation to innovation: Immune microenvironments, clonal lesion biology, and the emerging therapeutic pipeline
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218845 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026. Verfasst von Bindu Santhamma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Evestra, Inc, San Antonio, TX, USA. Hauptthemen laut MEDLINE: Endometriosis, Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, American Cancer Society Inc.
Abstract (Originalsprache)
Endometriosis is a chronic, estrogen-dependent inflammatory disease that, despite its benign histology, displays several cancer-relevant features, including clonal expansion, somatic alteration-associated lesion evolution, tissue invasion, apoptosis resistance, immune evasion, angiogenesis, fibrosis, and metabolic adaptation. These features are particularly important in ovarian endometriosis, where recurrent hemorrhage, iron-driven oxidative stress, and chronic inflammatory remodeling may promote malignant transformation. This review examines endometriosis through an oncologic framework by integrating current evidence on disease initiation, clonal lesion evolution, and the peritoneal, ovarian, and deep-infiltrating microenvironments. We discuss how epithelial, stromal, immune, endothelial, mesothelial, and neural components cooperate to support lesion survival, dissemination, vascularization, fibrosis, neuroinflammation, and treatment resistance. Particular attention is given to cancer-associated molecular programs, including PI3K-AKT-mTOR, RAS-MAPK, WNT/β-catenin, hypoxia, oxidative-stress, inflammatory, and epigenetic signaling, and their relationship to endometriosis-associated ovarian cancer. We also critically evaluate animal models, organoids, three-dimensional scaffolds, and microfluidic systems for their ability to reproduce lesion heterogeneity, microenvironmental interactions, therapeutic responses, and malignant progression. Finally, we assess current and emerging therapeutic strategies, emphasizing non-hormonal interventions directed against inflammatory, immune, fibrotic, angiogenic, metabolic, and oncogenic vulnerabilities, together with biomarker-guided and fertility-sparing approaches. Viewing endometriosis as a cancer-relevant inflammatory and clonal disease may reveal actionable mechanisms for precision treatment and interception of endometriosis-associated malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Evestra, Inc, San Antonio, TX, USA.
- Department of Medical Education, Texas Tech University Health Science Center, El Paso, TX, USA.
- Environmental and Occupational Health Sciences, University of Texas Houston, El Paso, TX, USA.
- Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Cracow, Poland.
- Department of Molecular and Translational Medicine, Texas Tech University Health Science Center, El Paso, TX, USA.
- VaRi Biosciences, Berlin, Germany.
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- American Cancer Society Inc
- Texas Tech University Health Sciences Center
- Lizanell and Colbert Coldwell Foundation
- National Institutes of Health
Zitieren
APA
Santhamma, B., Chacon, J., Deemer, E., Stary, D., Hernandez, S. A., Subramani, R., Lakshmanaswamy, R., Nickisch, K. J., Batra, S. K., & Nair, H. B. (2026). Endometriosis from initiation to innovation: Immune microenvironments, clonal lesion biology, and the emerging therapeutic pipeline. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218845
Vancouver
Santhamma B, Chacon J, Deemer E, Stary D, Hernandez SA, Subramani R, et al. Endometriosis from initiation to innovation: Immune microenvironments, clonal lesion biology, and the emerging therapeutic pipeline. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218845
BibTeX
@article{Santhamma2026,
author = {Santhamma, Bindu and Chacon, Jessica and Deemer, Eva and Stary, Dorota and Hernandez, Shayla A and Subramani, Ramadevi and Lakshmanaswamy, Rajkumar and Nickisch, Klaus J and Batra, Surinder K and Nair, Hareesh B},
title = {Endometriosis from initiation to innovation: Immune microenvironments, clonal lesion biology, and the emerging therapeutic pipeline},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218845}
}
EUVIMED